4SC Files Marketing Authorisation Application with EMA for Resminostat (Kinselby)
4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage c…
4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage c…
. New level 1 data from the MAXA Clinical Trial comparing standalone MagnetOs to the gold standard autograft in the ch…
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today anno…
The European Medicines Agency (EMA) has granted Orphan Drug Designation for resminostat for treatment of cutaneous T…
Wissenschaftlerinnen und Wissenschaftler vom Deutschen Krebsforschungszentrum (DKFZ) und vom Cambridge Stem Cell Instit…
4SC AG (4SC, FSE Prime Standard: VSC) announced that the results from the RESMAIN Study evaluating resminostat (Kinselby…
. The European Medicines Agency (EMA) has notified 4SC that it has accepted its Letter of Intent to Submit a Marketing…
4SC AG (4SC, FSE Prime Standard: VSC) has now filed with EMA its letter of intent to file for Marketing Authorization fo…
Resminostat met the primary endpoint in the RESMAIN study, demonstrating a statistically significant improvement in prog…
Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA2…